Business
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke
TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke Market $2.7 Billion by 2029 NEW
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S.\nGlobal Acute Ischemic Stroke Market $2.7 Billion by 2029\nNEW YORK, Sept. 20, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation. HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury (\"TBI\"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have been selected by Hoth Therapeutics, Inc. to support their important goal of developing a ready-to-use drug-device combination product for the treatment and/or prevention of secondary brain injury. Altasciences' purpose is to help companies like Hoth Therapeutics research and develop potentially life-saving therapeutics—as safely and as fast as possible.\" stated Ben Reed, General Manager, CDMO Services at Altasciences.\n\"Hoth is excited to announce this partnership and next milestone in our development of HT-TBI,\" stated Dr. Stefanie Johns, Chief Scientific Officer. \"We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs.\"\nThe HT-TBI formulation development and manufacturing work by Altasciences will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials.\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a ...